Trial · NCT02435212
Results by group174
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 174
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Overall Compliance Using Stick Pack or Tablet Counts in Iron Chelation Therapy (ICT)-naïve Participants During the Core Phase | DFX DT | 89.45 | 95% Confidence Interval 85.29 to 93.61 | percentage of compliance | |
| Percentage of Overall Compliance Using Stick Pack or Tablet Counts in Iron Chelation Therapy (ICT)-naïve Participants During the Core Phase | DFX Granule | 91.78 | 95% Confidence Interval 87.81 to 95.75 | percentage of compliance | |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in ICT naïve Participants During the Core Phase | DFX DT | Baseline | 2063.7 | 95% Confidence Interval 1807.17 to 2320.15 | μg/L |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in ICT naïve Participants During the Core Phase | DFX Granule | Baseline | 1955.5 | 95% Confidence Interval 1712.57 to 2198.49 | μg/L |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in ICT naïve Participants During the Core Phase | DFX DT | Week 25 | 2216.3 | 95% Confidence Interval 1929.59 to 2502.93 | μg/L |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in ICT naïve Participants During the Core Phase | DFX Granule | Week 25 | 2228.4 | 95% Confidence Interval 2011.69 to 2445.18 | μg/L |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in ICT naïve Participants During the Core Phase | DFX DT | Change from Baseline to Week 25 | 250.5 | 95% Confidence Interval -84.63 to 585.58 | μg/L |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in ICT naïve Participants During the Core Phase | DFX Granule | Change from Baseline to Week 25 | 340.0 | 95% Confidence Interval 115.48 to 564.59 | μg/L |
| Percentage of Overall Compliance Using Stick Pack or Tablet Counts in ICT-naïve Participants During the Core Phase | DFX DT | 91.57 | 95% Confidence Interval 87.65 to 95.49 | percentage of compliance | |
| Percentage of Overall Compliance Using Stick Pack or Tablet Counts in ICT-naïve Participants During the Core Phase | DFX Granule | 94.80 | 95% Confidence Interval 91.48 to 98.13 | percentage of compliance | |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in ICT naïve Participants During the Core Phase | DFX DT | 305.8 | 95% Confidence Interval 4.28 to 607.24 | μg/L | |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in ICT naïve Participants During the Core Phase | DFX Granule | 317.0 | 95% Confidence Interval 69.10 to 564.88 | μg/L | |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in Pre-treated Participants During the Core Phase | DFX DT | Change from Baseline to Week 25 | 59.0 | 95% Confidence Interval -210.88 to 328.79 | μg/L |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in Pre-treated Participants During the Core Phase | DFX Granule | Change from Baseline to Week 25 | 150.3 | 95% Confidence Interval -59.43 to 360.01 | μg/L |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in Pre-treated Participants During the Core Phase | DFX DT | Change from Baseline to Week 48 | 207.7 | 95% Confidence Interval -94.29 to 509.68 | μg/L |
| Change From Baseline in Serum Ferritin (SF) for Both Study Drug Formulations in Pre-treated Participants During the Core Phase | DFX Granule | Change from Baseline to Week 48 | 215.7 | 95% Confidence Interval -50.47 to 481.95 | μg/L |
| Change Over-time in Domain Score of Modified Satisfaction With Iron Chelation Therapy (mSICT) Using Patient Reported Outcomes (PRO) Questionnaires | DFX DT | Adherence (Week 2) | 9.5 | Standard Deviation 2.30 | score on a scale |
| Change Over-time in Domain Score of Modified Satisfaction With Iron Chelation Therapy (mSICT) Using Patient Reported Outcomes (PRO) Questionnaires | DFX Granule | Adherence (Week 2) | 7.6 | Standard Deviation 1.99 | score on a scale |
| Change Over-time in Domain Score of Modified Satisfaction With Iron Chelation Therapy (mSICT) Using Patient Reported Outcomes (PRO) Questionnaires | DFX DT | Adherence (Week 3) | 10.9 | Standard Deviation 4.95 | score on a scale |
| Change Over-time in Domain Score of Modified Satisfaction With Iron Chelation Therapy (mSICT) Using Patient Reported Outcomes (PRO) Questionnaires | DFX Granule | Adherence (Week 3) | 6.6 | Standard Deviation 0.79 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02435212/results